X4 Pharmaceuticals (NASDAQ:XFOR) vs. OKYO Pharma (NASDAQ:OKYO) Critical Review

OKYO Pharma (NASDAQ:OKYO) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Risk and Volatility

OKYO Pharma has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.

Insider and Institutional Ownership

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares OKYO Pharma and X4 Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
X4 Pharmaceuticals	N/A	-170.10%	-65.44%

Analyst Ratings

This is a summary of recent ratings for OKYO Pharma and X4 Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	0	0	1	0	3.00
X4 Pharmaceuticals	0	1	1	0	2.50

OKYO Pharma currently has a consensus target price of $7.00, suggesting a potential upside of 379.26%. X4 Pharmaceuticals has a consensus target price of $3.00, suggesting a potential upside of 175.23%. Given OKYO Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe OKYO Pharma is more favorable than X4 Pharmaceuticals.

Earnings and Valuation

This table compares OKYO Pharma and X4 Pharmaceuticals’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$13.27 million	N/A	N/A
X4 Pharmaceuticals	N/A	N/A	-$101.17 million	($0.60)	-1.82

Summary

OKYO Pharma beats X4 Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.